

RECEIVED

FEB 05 2001

TECH CENTER 1600/2333

C 2
SUB D2

7. (Twice Amended) A pharmaceutical composition for selectively [regulating] inhibiting mammalian tumor necrosis factor alpha in a mammal in need of such treatment consisting of

an effective amount of at least one active ingredient a synthetic nuclease resistant antisense oligodeoxynucleotide having a nucleotide sequence selected from the group consisting of SEQ. ID No. 4 and SEQ. ID No. 6 in a pharmaceutically physiologically acceptable carrier or diluent.

SUB D3

C 3

13. (Amended) A method of selectively regulating mammalian tumor necrosis factor alpha by [the steps of] targeting for treatment [the] a tumor necrosis factor alpha splice region and then specifically modify the region to [regulate] inhibit the mammalian tumor necrosis factor alpha.

SUB D4

14. (Amended) The method of claim 13 further including [the step of] administering an effective amount of a synthetic nuclease resistant antisense oligodeoxynucleotide which targets exon sequences flanking donor splice sites.

SUB D5

15. (Amended) A method of inhibiting tumor necrosis factor alpha by targeting for treatment [the] a tumor necrosis factor alpha splice region thereby inhibiting tumor necrosis factor alpha.

16. (Amended) The method of claim 15 further including [the step of] administering an effective amount of a synthetic nuclease resistant antisense oligodeoxynucleotide which targets exon sequences flanking donor splice sites.

REMARKS

Claims 3-13 are currently pending in the application. Only claims 3, 5 and 9 are in independent form.